A $40 Generic Version of a Twice-Yearly HIV Prevention Shot Clears Its First FDA Hurdle
On November 2, 2026, the U.S. Food and Drug Administration gave tentative approval to the first generic version of lenacapavir, a twice-yearly injection that prevents HIV infection. Dr. Reddy's Laboratories of India makes the generic. Under a pricing agreement, it will cost $40 per person per year in 120 low- and middle-income countries. In the United States, the branded product, Yeztugo, lists for about $28,000 a year before insurance, AFP reports.
Lenacapavir works as pre-exposure prophylaxis (PrEP): a person who does not have HIV takes it to lower the risk of getting HIV. The drug blocks the capsid, the protein shell around the virus's genetic material. Daily oral PrEP pills won U.S. approval in 2012, but they only protect people who take them consistently. Cabotegravir, an injectable approved in 2021, needs a shot every two months. Lenacapavir stretches the gap to six months.
What the trials showed
Two phase 3 trials, PURPOSE 1 and PURPOSE 2, supplied the evidence. In PURPOSE 1, none of the 2,134 cisgender women and adolescent girls in South Africa and Uganda who got lenacapavir acquired HIV, according to the trial's New England Journal of Medicine paper. In PURPOSE 2, two infections occurred among 2,179 cisgender men, transgender women, transgender men and gender-diverse participants. Gilead Sciences, which developed the drug, reports that at least 99.9% of trial participants on twice-yearly lenacapavir stayed HIV negative.
The FDA approved Gilead's product for prevention on June 18, 2025. The World Health Organization recommended it as an additional PrEP option on July 14, 2025. The journal Science named lenacapavir its 2024 Breakthrough of the Year.
Lenacapavir is not a vaccine, and it does not cure HIV. People must test negative before starting and before each injection, per Gilead's U.S. prescribing information, because the drug alone cannot control an infection that is already there. Protection depends on keeping to the six-month schedule.
How a decade became 16 months
People in lower-income countries often wait a decade or more for a generic version of a new medicine. Lenacapavir's wait ran about 16 months, and the groundwork came before the generic existed. In late 2024, Gilead granted voluntary licenses to six generic manufacturers, Dr. Reddy's among them. In September 2025, Unitaid, the Wits Reproductive Health and HIV Institute (Wits RHI), CHAI and Dr. Reddy's announced a deal that paired the $40 price with financial, technical and regulatory support.
The regulatory route moved fast too. Dr. Reddy's put lenacapavir's prevention and treatment uses into one application under the FDA's 505(b)(2) pathway, which lets a company rely partly on existing data. The FDA granted priority review, which targets a decision within six months. CHAI's release calls the result one of the fastest timelines to approval for a major HIV innovation to date.
What happens next
Tentative approval means the generic met FDA standards for safety, efficacy and quality, but patent and exclusivity rules block its sale in the United States. Outside the U.S., the decision still counts. CHAI notes it allows U.S. government procurement. Jessica Burry, a technical officer at Unitaid, told Reuters that some countries could fast-track their own approvals by relying on the FDA's review. First supplies should reach a few countries by the end of 2026, with Zambia among the first, according to Unitaid. Broader availability follows in 2027.
Demand already exists. More than 125,000 people in 10 early adopter African countries have started Gilead's branded lenacapavir. An estimated 1.2 million people acquired HIV last year, Unitaid's Carmen Perez-Casas told AFP.
📍 Multiple Perspectives on the Story
Access planned from the start
For Unitaid, Wits RHI and CHAI, the timeline is the result. Early licensing, an early price commitment and hands-on support for the generic maker moved access to the front of the process. Unitaid's executive director, Philippe Duneton, ties the speed to faster access for young women in Africa. CHAI chief executive Neil Buddy Shah says the 16-month path should become the new standard for global health.
Two clinic visits instead of a daily pill
For a person at risk of HIV, the schedule changes most. A daily pill asks for a decision every morning to prevent a disease the person does not have. Two injections a year replace that routine with two clinic visits and an HIV test before each one. AFP quotes Unitaid describing the $40 price as comparable to daily prevention pills.
A long-acting injection made at scale
Dr. Reddy's was the first of the six licensed manufacturers to clear FDA review, Reuters reports. A long-acting injectable needs precise formulation and large-scale production, and Deepak Sapra, who leads the company's API and services business, credits its manufacturing expertise for meeting the $40 target. Five other licensees could widen supply if their applications also clear review. The sources give no production volumes.
Approval comes before access
November 2 marks a regulatory milestone, not a delivery result. The approval puts no doses in U.S. pharmacies and none in clinics across the 120 countries yet. National approvals, procurement funding, trained providers, HIV testing before each injection and follow-up for missed doses all still have to happen. Saiqa Mullick, director of implementation science at Wits RHI, says it in the partners' own release: "an affordable drug alone is not enough."
Strong results in the groups studied
PURPOSE 1 enrolled cisgender women and adolescent girls in South Africa and Uganda. PURPOSE 2 enrolled cisgender men, transgender people and gender-diverse people. The strongest evidence applies to those populations. In PURPOSE 1, the comparison groups on daily pills had 16 infections among 1,068 women on one pill and 39 among 2,136 on the other, against zero on lenacapavir, per the NEJM paper.
What this does and does not mean
The settled part is a price, a timeline and a trial record: $40 per person per year in 120 countries, about 16 months from originator approval to the first generic tentative approval, and at least 99.9% of trial participants on lenacapavir staying HIV negative. Delivery is still open. First generic supplies are due in a few countries before the end of 2026. In 2027, national regulators, funders, clinics and communities will decide how many people actually get two injections a year, on schedule, with a test before each one.
Frequently Asked Questions
What did the FDA approve on November 2, 2026?
The FDA gave tentative approval to Dr. Reddy's Laboratories' generic version of lenacapavir, a twice-yearly injection that prevents HIV. Tentative approval means the drug met FDA standards for safety, efficacy and quality, but patent and exclusivity rules block its sale in the United States.
How much will generic lenacapavir cost?
$40 per person per year in the 120 low- and middle-income countries covered by Gilead's voluntary license, under a September 2025 pricing agreement among Unitaid, Wits RHI, CHAI and Dr. Reddy's. The branded product, Yeztugo, costs about $28,000 per year in the United States before insurance.
How well does lenacapavir prevent HIV?
In the PURPOSE 1 trial, none of the 2,134 cisgender women and adolescent girls who received lenacapavir acquired HIV. In PURPOSE 2, two of 2,179 participants did. Gilead reports that at least 99.9% of trial participants on twice-yearly lenacapavir stayed HIV negative. It is not a vaccine and does not cure HIV.
When will the generic reach patients?
First supplies are expected in a few countries by the end of 2026, with broader availability in 2027. Unitaid told Reuters that Zambia could be one of the first. Each country still needs its own regulatory approval, funding and trained providers.